Andersen Disease (Type IV)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Andersen Disease (Type IV) is a rare inherited disorder that affects the body's ability to properly store and use glycogen, a form of stored sugar used for energy. It primarily impacts the liver and muscle tissues, leading to problems with energy production. People with this condition often experience muscle weakness, liver enlargement, and sometimes heart problems. The disease is caused by a defect in an enzyme that helps build the correct structure of glycogen, resulting in abnormal glycogen deposits. This abnormal storage can cause damage to affected organs and impair their function. The condition usually appears in infancy or early childhood and can vary in severity.
Clinical Definition
GSD IV (Andersen disease) is an autosomal recessive GBE1 glycogen branching-enzyme deficiency. Poorly branched, insoluble polyglucosan injures affected tissues. Classic childhood disease features hepatomegaly and progressive cirrhosis, but severity varies; congenital neuromuscular and later-onset forms also occur. Related adult polyglucosan body disease predominantly affects the nervous system.
Inciting Event
No specific external trigger; disease onset is due to inherited enzyme deficiency.
Timing reflects the inherited GBE1-related phenotype, rather than a defined postnatal trigger.
Latency Period
Onset ranges from before birth to adulthood; classic hepatic disease usually becomes apparent in infancy.
Some forms are rapidly severe; others progress slowly or have relatively stable hepatic involvement.
Diagnostic Delay
Early symptoms such as hepatomegaly and hypotonia are nonspecific and often misattributed to other metabolic or infectious diseases.
Lack of awareness of Andersen disease (Type IV glycogen storage disease) leads to delayed genetic testing.
Overlap with other glycogen storage diseases complicates early diagnosis without enzyme assay or genetic confirmation.
Clinical Presentation
Signs & Symptoms
Hepatomegaly with abdominal distension is a primary clinical feature.
Muscle weakness and hypotonia lead to delayed motor milestones.
Failure to thrive and poor feeding are common in infancy.
Respiratory difficulties may occur due to muscle involvement.
Jaundice and signs of liver dysfunction can be present.
History of Present Illness
Progressive hepatomegaly with abdominal distension is a common initial complaint.
Development of muscle weakness and hypotonia occurs as disease progresses.
Failure to thrive and feeding difficulties are frequently reported in affected infants.
Cardiac and respiratory involvement may occur early in congenital neuromuscular disease, or later in other phenotypes.
Past Medical History
Review growth, development, feeding and respiratory history; recurrent infections are not a defining primary feature.
Prenatal reduced movement or neonatal hypotonia may precede diagnosis; a previously normal history is not required.
Family History
Positive family history of early childhood liver disease or unexplained infant death may be present.
Consanguineous parents increase risk of autosomal recessive inheritance of GBE1 mutations.
Siblings may have similar symptoms or confirmed diagnosis of Andersen disease.
Physical Exam Findings
Hepatomegaly due to glycogen accumulation in the liver is a hallmark finding.
Hypotonia and muscle weakness are common due to glycogen storage in muscle tissue.
Failure to thrive and growth retardation are often observed in affected infants.
Cardiomyopathy may be present in some cases due to glycogen deposition in cardiac muscle.
Protuberant abdomen from enlarged liver and possible ascites.
Diagnostic Workup
Diagnostic Criteria
Confirm with biallelic pathogenic/likely pathogenic GBE1 variants or deficient branching-enzyme activity in appropriate tissue. Biopsy can assess liver disease or support unresolved cases; histology alone is insufficient.
Pathophysiology
Key Mechanisms
Deficiency of glycogen branching enzyme (GBE1) leads to accumulation of abnormal glycogen with fewer branch points, causing insoluble polyglucosan bodies.
Impaired glycogen branching results in poorly soluble glycogen deposits in liver, muscle, and heart tissues, disrupting cellular function.
Accumulation of polyglucosan bodies causes progressive organ dysfunction, especially in the liver and skeletal muscle.
The abnormal glycogen structure triggers hepatomegaly and muscle weakness due to cellular damage and energy metabolism impairment.
| Involvement | Details |
|---|---|
| Organs | Liver is the main organ affected, presenting with hepatomegaly, progressive fibrosis, and cirrhosis due to abnormal glycogen storage. |
Skeletal muscle may also be involved in some cases, leading to muscle weakness and hypotonia. | |
| Tissues | Liver tissue is primarily involved, showing accumulation of abnormal glycogen with fewer branches, leading to hepatocyte dysfunction and fibrosis. |
| Cells | Hepatocytes are the primary cells affected in Andersen disease due to defective glycogen branching enzyme leading to abnormal glycogen accumulation. |
Polyglucosan can also accumulate in muscle and neural cells, depending on phenotype; GBE1 deficiency is not liver-limited. | |
| Chemical Mediators | Glycogen branching enzyme (GBE) deficiency caused by mutations in the GBE1 gene leads to accumulation of poorly branched glycogen. |
Branching enzyme forms alpha-1,6 branch points; deficiency leaves longer, poorly branched glucose chains with reduced solubility. |
Treatments
Pharmacological Treatments
No disease-specific pharmacological treatment is listed for this topic.
Non-pharmacological Treatments
Liver transplantation treats advanced hepatic disease, not the underlying enzyme defect throughout the body; cardiac/neuromuscular disease may persist or progress.
Supportive care includes management of cirrhosis complications such as portal hypertension and ascites.
Nutritional support with adequate caloric intake is important to prevent malnutrition and support growth.
Prevention
Pharmacological Prevention
No established pharmacological prevention exists; management focuses on supportive care.
Enzyme replacement therapy is not currently available for Andersen disease.
Treat documented hypoglycemia when present; routine glucose supplementation is not a universal GSD IV treatment.
Non-pharmacological Prevention
Genetic counseling explains recurrence and reproductive testing options; if both parents are carriers, each pregnancy has a 25% affected risk.
Regular monitoring of liver function and cardiac status to detect early complications.
Individualize nutrition and fasting precautions to growth, liver function and measured glucose.
Early referral for liver transplantation evaluation in progressive cases.
Outcome & Complications
Complications
Liver failure from progressive hepatic damage is a major cause of morbidity.
Portal hypertension due to cirrhosis can lead to variceal bleeding.
Respiratory failure from muscle weakness and recurrent infections.
Hypoglycemia can occur, particularly with liver dysfunction; it is not the defining early feature of GSD IV.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Andersen Disease (Type IV) versus Pompe Disease (Type II Glycogen Storage Disease)
Andersen Disease (Type IV) | Pompe Disease (Type II Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance caused by mutations in the GBE1 gene | Autosomal recessive inheritance due to mutations in the GAA gene |
Variable onset, often in infancy or childhood, with hepatomegaly and muscle weakness | Infantile Pompe often causes hypertrophic cardiomyopathy and hypotonia; late-onset Pompe causes limb-girdle/respiratory weakness, often without major cardiac disease. |
Normal acid alpha-glucosidase with deficient glycogen branching enzyme activity | Elevated creatine kinase and acid alpha-glucosidase deficiency |
Abnormal glycogen structure with fewer branch points in liver and muscle | Lysosomal glycogen accumulation in cardiac and skeletal muscle |
Andersen Disease (Type IV) versus McArdle Disease (Type V Glycogen Storage Disease)
Andersen Disease (Type IV) | McArdle Disease (Type V Glycogen Storage Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive due to mutations in the PYGM gene |
Onset typically in infancy or early childhood with hepatomegaly | Symptoms often begin in childhood, although diagnosis may be delayed until adulthood. |
Normal muscle phosphorylase with deficient glycogen branching enzyme activity | Elevated serum creatine kinase and absent muscle phosphorylase activity |
Progressive hepatomegaly and liver dysfunction with possible muscle involvement | Exercise-induced cramps, possible rhabdomyolysis/myoglobinuria and a second-wind phenomenon; primary liver disease is not typical. |
Andersen Disease (Type IV) versus Cori Disease (Type III Glycogen Storage Disease)
Andersen Disease (Type IV) | Cori Disease (Type III Glycogen Storage Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive due to mutations in the AGL gene |
Deficiency of branching enzyme activity with abnormal glycogen structure | Deficiency of debranching enzyme activity with accumulation of limit dextrin |
Hepatic fibrosis/cirrhosis is characteristic; severe fasting hypoglycemia is not the usual early hallmark. | Hepatomegaly with ketotic hypoglycemia of variable severity; IIIa involves muscle, whereas IIIb is predominantly hepatic. |
Reduced glycogen branching enzyme activity | Biallelic pathogenic AGL variants or deficient debranching-enzyme activity. |
Andersen Disease (Type IV) versus Glycogen Storage Disease Type I (Von Gierke Disease)
Andersen Disease (Type IV) | Glycogen Storage Disease Type I (Von Gierke Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive: G6PC1 (Ia) or SLC37A4 (Ib). |
Poorly branched glycogen and hepatic injury; glucose may remain normal early. | Marked fasting hypoglycemia, hyperlactatemia, hyperuricemia and hyperlipidemia are typical when poorly controlled. |
Progressive liver disease with abnormal glycogen branching and fibrosis | Fasting metabolic instability and hepatomegaly with structurally normal glycogen; severity depends on metabolic control. |
Deficient glycogen branching enzyme activity | Biallelic pathogenic variants in G6PC1 or SLC37A4 establish the subtype; glucose-6-phosphatase enzyme deficiency describes Ia. |